Anticholinergic Use Linked to Faster Physical Decline in Older Adults, finds research

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-07-19 03:00 GMT   |   Update On 2025-07-19 05:57 GMT
Advertisement

Researchers have found in a new cohort study that higher exposure to anticholinergic medications was associated with an accelerated decline in physical performance. This decline was clinically meaningful, highlighting the importance of minimizing anticholinergic use to support healthy aging. The study was published in JAMA Network by Shelly L. and colleagues.

The research was performed in the Adult Changes in Thought (ACT) study, a longitudinal population-based cohort from Kaiser Permanente Washington. Data were accrued from February 1994 through March 2020, and analysis was between January 2023 and December 2024. There were 4283 participants aged 65 years or more included in the analysis. Eligibility criteria included having at least two study visits and a minimum of 10 years of enrollment before the study index date. Of the total sample, 4210 individuals (58.6% women, mean age 74.3 years) were included in the gait speed analysis, while 4200 (58.5% women, mean age 74.5 years) contributed to the grip strength evaluation. The average follow-up time was 8.2 years.

The investigators assessed anticholinergic exposure in multiple dimensions. Two traditional measures presumed constant effects of constant exposure:

• 10-year Total Standardized Daily Dose (TSDD)

• 2-year mean Standardized Daily Dose (mSDD)

The study also used WCE models to account for time-varying effects over varying windows (2, 4, 6, 8, or 10 years). These models were intended to express the dynamic interaction between exposure duration and physical deterioration. The main outcomes were gait speed (meters per second) and grip strength (kilograms). Generalized Estimating Equations (GEE) adjusted linear models compared the rate of decline by exposure group, and model fit was examined with the quasi-information criterion (QIC).

Advertisement

Key Findings

• Relative to nonusers, individuals with TSDD ≥1096 over 10 years had a significantly larger decrease in gait speed of −0.0132 m/s per year (95% CI, −0.0193 to −0.0070).

• Individuals with 2-year mSDD ≥0.5 walked more slowly with a reduction of −0.0101 m/s per year (95% CI, −0.0174 to −0.0029).

• The 4-year WCE model most fully explained gait speed decline and indicated that a 1-unit weighted mSDD increase was associated with a −0.0034 m/s per year (95% CI, −0.0048 to −0.0019) decline in gait speed.

• Grip strength was not substantially affected under standard exposure models.

• But the 6-year WCE model of grip strength had a decrease of −0.0329 kg per year (95% CI, −0.0612 to −0.0046) for each unit rise in weighted mSDD, indicating a postponed but significant effect on muscle strength.

This cohort study identified that increased anticholinergic exposure was linked with faster physical decline, namely reduced gait speed and weaker grip strength. Health care practitioners can take steps to minimize or replace such medications when feasible to facilitate healthier aging outcomes.

Reference:

Gray SL, Su Y, Eshetie TC, LaCroix AZ, Marcum ZA, Yu O. Cumulative Anticholinergic Exposure and Change in Gait Speed and Grip Strength in Older Adults. JAMA Netw Open. 2025;8(7):e2519819. doi:10.1001/jamanetworkopen.2025.19819

Tags:    
Article Source : JAMA Network

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Medical Bulletin 19/July/2025